ATA81279A - Verfahren zur herstellung von neuen 9alpha,21- -dihalogen-11beta,17alpha-dihydroxy-6alpha- -fluor-16alpha-methyl-pregna-1,4-dien-3,20-dion -verbindungn - Google Patents

Verfahren zur herstellung von neuen 9alpha,21- -dihalogen-11beta,17alpha-dihydroxy-6alpha- -fluor-16alpha-methyl-pregna-1,4-dien-3,20-dion -verbindungn

Info

Publication number
ATA81279A
ATA81279A AT81279A AT81279A ATA81279A AT A81279 A ATA81279 A AT A81279A AT 81279 A AT81279 A AT 81279A AT 81279 A AT81279 A AT 81279A AT A81279 A ATA81279 A AT A81279A
Authority
AT
Austria
Prior art keywords
9alpha
6alpha
16alpha
11beta
17alpha
Prior art date
Application number
AT81279A
Other languages
English (en)
Other versions
AT363201B (de
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25717430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA81279(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CH1615175A external-priority patent/CH621801A5/de
Priority claimed from LU75903A external-priority patent/LU75903A1/xx
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Priority to AT0081279A priority Critical patent/AT363201B/de
Publication of ATA81279A publication Critical patent/ATA81279A/de
Application granted granted Critical
Publication of AT363201B publication Critical patent/AT363201B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT0081279A 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha- AT363201B (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH1615175A CH621801A5 (en) 1975-12-12 1975-12-12 Process for the preparation of polyhalosteroids
LU75903A LU75903A1 (de) 1976-09-29 1976-09-29
AT913976A AT357703B (de) 1975-12-12 1976-12-10 Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-

Publications (2)

Publication Number Publication Date
ATA81279A true ATA81279A (de) 1980-12-15
AT363201B AT363201B (de) 1981-07-27

Family

ID=25717430

Family Applications (2)

Application Number Title Priority Date Filing Date
AT913976A AT357703B (de) 1975-12-12 1976-12-10 Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT913976A AT357703B (de) 1975-12-12 1976-12-10 Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen

Country Status (16)

Country Link
US (1) US4619921A (de)
JP (1) JPS5289662A (de)
AT (2) AT357703B (de)
AU (1) AU508224B2 (de)
CA (1) CA1056371A (de)
DD (1) DD128683A5 (de)
DE (1) DE2655570A1 (de)
DK (1) DK143708C (de)
ES (1) ES454120A1 (de)
FR (1) FR2334363A1 (de)
GB (1) GB1537130A (de)
HU (1) HU175583B (de)
IE (1) IE44473B1 (de)
IL (1) IL51087A (de)
NL (1) NL7613791A (de)
NZ (1) NZ182836A (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209140B (it) * 1979-11-16 1989-07-10 Prochem Ets 6 alfa-fluoro-prednisolone 17,21-diesteri.
EP0078235A3 (de) * 1981-10-23 1983-06-29 Ciba-Geigy Ag Dihalogenierte Steroide
IT1319663B1 (it) * 2000-11-17 2003-10-23 Farmabios Srl Processo per la preparazione di fluoro-steroidi.
IL162140A0 (en) * 2001-11-29 2005-11-20 Taro Pharmaceuticals Usa Inc Method for the preparation of l-alpha-fluoro corticosteroids
US20040138192A1 (en) * 2003-01-13 2004-07-15 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
AU2004268847A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
WO2006110534A2 (en) 2005-04-07 2006-10-19 Taro Pharmaceuticals U.S.A., Inc. A process for preparing a crystalline form of halobetasol propionate
EP1934219A1 (de) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituierte pyrazolo-[3,4-b]-pyridine als phosphodiesterase-inhibitoren
EP1948167A1 (de) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Zusammensetzungen von phosphodiesterase-typ-iv-hemmern
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1958947A1 (de) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitoren für Phosphodiesterase Typ 4
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
AU2008224541B2 (en) * 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
DK3310389T3 (da) 2015-06-18 2020-08-10 Bausch Health Ireland Ltd Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL241055A (de) * 1958-07-09
US3499016A (en) * 1958-08-04 1970-03-03 Upjohn Co 6alpha-fluoro-16alpha-methyl derivatives of the pregnane series
GB898292A (en) * 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
CH534144A (de) * 1967-11-17 1973-02-28 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
US3718673A (en) * 1971-02-01 1973-02-27 Du Pont Process for the preparation of 21-chloro-6,6,9alpha-trifluoro-11beta, alpha, 17alpha-trihydroxy-1,4-pregnadien-3,20-dione 16,17-ketals and selected intermediates
US4018918A (en) * 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
US3992422A (en) * 1975-08-14 1976-11-16 Schering Corporation Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy-20-keto-pregnenes

Also Published As

Publication number Publication date
DK557876A (da) 1977-06-13
AU2047276A (en) 1978-06-15
ES454120A1 (es) 1978-02-16
AU508224B2 (en) 1980-03-13
FR2334363B1 (de) 1980-03-14
ATA913976A (de) 1979-12-15
IL51087A (en) 1980-06-30
CA1056371A (en) 1979-06-12
GB1537130A (en) 1978-12-29
IE44473L (en) 1977-06-12
FR2334363A1 (fr) 1977-07-08
DE2655570A1 (de) 1977-06-16
IE44473B1 (en) 1981-12-16
DD128683A5 (de) 1977-12-07
DK143708C (da) 1982-03-15
NL7613791A (nl) 1977-06-14
IL51087A0 (en) 1977-02-28
JPS5289662A (en) 1977-07-27
AT363201B (de) 1981-07-27
NZ182836A (en) 1979-01-11
HU175583B (hu) 1980-09-28
AT357703B (de) 1980-07-25
US4619921A (en) 1986-10-28
DK143708B (da) 1981-09-28

Similar Documents

Publication Publication Date Title
AT351266B (de) Verfahren zur herstellung von neuen poly- urethanen
ATA81279A (de) Verfahren zur herstellung von neuen 9alpha,21- -dihalogen-11beta,17alpha-dihydroxy-6alpha- -fluor-16alpha-methyl-pregna-1,4-dien-3,20-dion -verbindungn
AT360663B (de) Verfahren zur herstellung von neuen 6,7- -benzomorphanen
AT344896B (de) Verfahren zur herstellung von neuen piperazinyliminorifamycinen
AT349633B (de) Verfahren zur herstellung von neuen dauno- saminylanthracylcinonen
AT356671B (de) Verfahren zur herstellung von neuen n,n'-thio- -di-carbamaten
AT353956B (de) Verfahren zur herstellung von neuen cephalosporinantibiotika
ATA585876A (de) Verfahren zur herstellung von neuen 2-benzimidazolylcarbamaten
AT354434B (de) Verfahren zur herstellung von neuen 1,4- diphenyl-3-pyrazolin-5-onen
AT359220B (de) Verfahren zur herstellung von neuen pregnan- derivaten
AT363197B (de) Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta, 17alpha-dihydroxy-6alpha-fluor-16beta-methyl-pregna-1,4-dien-3,20-dion-verbindungen
AT344150B (de) Verfahren zur herstellung von neuen cyclohexylphenylen
AT343624B (de) Verfahren zur herstellung von neuen n-alkyl -2,4-dinitro-6- trifluormethyldiphenylaminen
AT357698B (de) Verfahren zur herstellung von neuen octapeptid- derivaten
AT353989B (de) Verfahren zur herstellung von neuen 11,12- ungesaettigten 9alpha-fluorsteroiden
AT356298B (de) Verfahren zur herstellung von neuen 6-amino- methylcholest-5-enen
AT345801B (de) Verfahren zur herstellung von neuen 1-phenoxy- 2-acyloxy-3-amino-propanderivaten
ATA81179A (de) Verfahren zur herstellung von neuen 9alpha, 21- -dihalogen-11beta, 17alpha-dihydroxy-6alpha- -fluor-16alpha-methyl-pregna-1,4-dien-3-20- -dion-verbindungen
ATA81079A (de) Verfahren zur herstellung von neuen 9alpha,21- -dihalogen-11beta,17alpha-dihydroxy-6alpha- -flour-16alpha-methyl-pregna-1,4-dien-3,20- -dion-verbindungen
AT356125B (de) Verfahren zur herstellung von neuen 1-aryloxy- -2,3-epoxypropanen
AT342617B (de) Verfahren zur herstellung von neuen 1-methyl-3-alkyl-7-oxoalkylxanthinen
AT347967B (de) Verfahren zur herstellung von neuen biguaniden
ATA460476A (de) Verfahren zur herstellung von neuen monodeuterierten prostaglandinen
AT353432B (de) Verfahren zur herstellung von neuen halogen- pregnadienen
ATA491279A (de) Verfahren zur herstellung von neuen 2,9-alpha-

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties